Trial Profile
A Randomized, Double-blind, Comparative Study of Abiraterone Acetate Plus Low-dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk, Metastatic Hormone-naive Prostate Cancer (mHNPC)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; LHRH receptor agonists; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms LATITUDE
- Sponsors Janssen Research & Development; Janssen-Cilag
- 01 Mar 2023 Results (n=1058) assessing to build and validate a multivariable prognostic model to predict overall survival in metastatic castrate sensitive prostate cancer, published in the Prostate Cancer and Prostatic Diseases.
- 01 Mar 2023 Results of an exploratory analysis of LATITUDE trial (n=1125) assessing the association of dynamic change in patient-reported pain with survival in metastatic castrate sensitive prostate cancer receiving either ADT plus abiraterone versus ADT alone, published in the Prostate Cancer and Prostatic Diseases.
- 28 Nov 2022 Results(n=217) assessing Clinical Outcomes of First Subsequent Therapies After Abiraterone Acetate Plus Prednisone for High-Risk Metastatic Castration-Sensitive Prostate Cancer published in the Targeted Oncology